Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
…, K Chatzidionysiou, H Asgeirsson, Å Parke, O Blennow… - Jama, 2021 - jamanetwork.com
Importance Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
for COVID-19 have variously reported benefit, no effect, and harm. Objective To estimate the …
[HTML][HTML] COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …
[HTML][HTML] Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a …
P Bergman, O Blennow, L Hansson, S Mielke… - …, 2021 - thelancet.com
Background Patients with immunocompromised disorders have mainly been excluded from
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …
[PDF][PDF] Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
Many immunocompromised patients mount suboptimal humoral immunity after SARS-CoV-2
mRNA vaccination. Here, we assessed the single-cell profile of SARS-CoV-2-specific T …
mRNA vaccination. Here, we assessed the single-cell profile of SARS-CoV-2-specific T …
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
…, F Marchesi, O Blennow… - Blood, The Journal …, 2022 - ashpublications.org
Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states
Suboptimal immunity to SARS-CoV-2 mRNA vaccination has frequently been observed in
individuals with various immunodeficiencies. Given the increased antibody evasion properties …
individuals with various immunodeficiencies. Given the increased antibody evasion properties …
[HTML][HTML] Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation
M Uhlin, H Wikell, M Sundin, O Blennow… - …, 2014 - ncbi.nlm.nih.gov
Allogeneic hematopoietic stem cell transplantation is a successful treatment for hematologic
malignancies and a variety of genetic and metabolic disorders. In the period following stem …
malignancies and a variety of genetic and metabolic disorders. In the period following stem …
Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines
…, C Viscoli, M Aljurf, D Averbuch, R Barnes, O Blennow… - Journal of Infection, 2018 - Elsevier
Objectives Fluoroquinolone (FQ) prophylaxis was recommended in 2005 by European
Conference on Infections in Leukemia (ECIL) for patients with prolonged neutropenia. In …
Conference on Infections in Leukemia (ECIL) for patients with prolonged neutropenia. In …
[HTML][HTML] Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study
…, M Ackefors, S Berglund, O Blennow… - Biology of Blood and …, 2011 - Elsevier
We analyzed the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) over
the past 2 decades. Between 1992 and 2009, 953 patients were treated with HSCT, mainly …
the past 2 decades. Between 1992 and 2009, 953 patients were treated with HSCT, mainly …
Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report
O Blennow, J Salmanton‐García… - American journal of …, 2022 - Wiley Online Library
To the Editor: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has
caused high mortality in patients with hematological malignancies (HM). 1 The newly …
caused high mortality in patients with hematological malignancies (HM). 1 The newly …
